, Volume 61, Issue 5, pp 573–578 | Cite as

Topical Corticosteroids in Nasal Polyposis

Review Article


Nasal polyps are the common end-point of a number of conditions characterised by inflammation and are rarely ‘curable’ in its true sense. After consideration of the underlying aetiology and confirmation of the diagnosis, they are normally managed by a combination of medical and surgical interventions. Of these, topical corticosteroids have proved to be the medical treatment of choice.

The objectives of the medical management are to eliminate or reduce the size of polyps, re-establish nasal airway and nasal breathing, improve or restore the sense of smell, and prevent recurrence of nasal polyps. The mechanism of action of corticosteroids may be by a multifactorial effect on various aspects of the inflammatory reaction, the effect being initiated by their binding to a specific cytoplasmic glucocorticoid receptor. At a cellular level, there is a reduction in the number of antigen-presenting cells, in the number and activation of T cells, in the number of mast cells, and in the number and activation of eosinophils.

When polyps are large (grade 3) topical medication is difficult to instil in a very blocked nose and surgery or short term systemic corticosteroids may be required. Topical corticosteroids are of use in the primary treatment of nasal polyps when they are of a small or medium size (grades 1 and 2) and in the maintenance of any therapeutic improvement.

The efficacy of topical corticosteroids such as betamethasone sodium phosphate nose drops, beclomethasone dipropionate, fluticasone propionate and budesonide nasal sprays in reducing polyp size and rhinitis symptoms has been demonstrated in several randomised, placebo-controlled trials. Beclomethasone dipropionate, flunisolide and budesonide sprays have also been shown to delay the recurrence of polyps after surgery. Placebo-controlled studies of agents that have shown a significant clinical effect in the management of nasal polyposis are reviewed.


  1. 1.
    Baumgarten C, Kunkek G, Rudolph R, et at. Histopathologic examinations of nasal polyps of different aetiology. Arch Otolaryngol 1980; 226: 187–97Google Scholar
  2. 2.
    Settipane GA. Epidemiology. In: Settipane GA, Lund VJ, Bernstein JM, et al., editors. Nasal polyps: epidemiology, pathogenesis and treatment. Providence (RI): OceanSide Publications, Inc., 1997: 17–24Google Scholar
  3. 3.
    Mygind N. Advances in the medical treatment of nasal polyps. Allergy 1999; 54 Suppl. 53: 12–6PubMedCrossRefGoogle Scholar
  4. 4.
    Mygind N, Lildholdt T. Medical management. In: Settipane GA, Lund VJ, Bernstein JM, et al., editors. Nasal polyps: epidemiology, pathogenesis and treatment. Providence (RI): OceanSide Publications, Inc., 1997: 147–55Google Scholar
  5. 5.
    Kanai N, Denburg J, Jordana M, et al. Nasal polyp inflammation. Effect of topical nasal steroid. Am J Respir Crit Care Med 1994; 150: 1094–100Google Scholar
  6. 6.
    Kim YK, Nakagawa N, Nakano K, et al. Stem cell factor in nasal polyposis and allergic rhinitis: increased expression by structural cells is suppressed by in vivo topical corticosteroids. J Allergy Clin Immunol 1997; 100: 389–99PubMedCrossRefGoogle Scholar
  7. 7.
    Meyer JE, Berner I, Teran LM, et al. RANTES production by cytokin-stimulated nasal fibroblasts: its inhibition by glucocorticoids. Int Arch Allergy Immunol 1998; 117(1): 60–7PubMedCrossRefGoogle Scholar
  8. 8.
    Saunders MW, Wheatley AH, George SJ, et al. Do corticosteroids induce apoptosis in nasal polyp inflammatory cells? In vivo and in vitro studies. Laryngoscope 1999; 109(5): 785–90PubMedCrossRefGoogle Scholar
  9. 9.
    Lund VJ, Mackay IS. Staging in rhinosinusitis. Rhinology 1993; 31: 183–4PubMedGoogle Scholar
  10. 10.
    Lund VJ, Kennedy DW. Quantification for staging sinusitis. Ann Otol Rhinol Laryngol 1995; 104 Suppl. 167: 17–21Google Scholar
  11. 11.
    Mackay IS, Lund VJ. Imaging and staging. In: Mygind N, Lildholdt T, editors. Nasal polyps: an inflammatory disease and its treatment. Copenhagen: Munksgaard, 1997: 137–44Google Scholar
  12. 12.
    Sorensen H, Mygind N, Tygstrup I, et al. Histology of nasal polyps of different aetiology. Rhinology 1997; 15: 121–8Google Scholar
  13. 13.
    Holmstrom M. Clinical performance of fluticasone propionate nasal drops. Allergy 1999; 54: 21–5PubMedCrossRefGoogle Scholar
  14. 14.
    Chalton R, Mackay I, Wilson R, et al. Double blind, placebo controlled trial of betamethasone nasal drops for nasal polyposis. BMJ 1985; 29: 788CrossRefGoogle Scholar
  15. 15.
    Mygind N, Pedersen CB, Prytz S, et al. Treatment of nasal polyps with intranasal beclomethasone dipropionate aerosol. Clin Allergy 1975; 5: 159–64PubMedCrossRefGoogle Scholar
  16. 16.
    Deuschl H, Drettner B. Nasal polyps treated by beclomethasone nasal aerosol. Rhinology 1977; 15: 17–23PubMedGoogle Scholar
  17. 17.
    Lund V, Flood J, Sykes A, et al. Effect of fluticasone in severe polyposis. Arch Otolaryngol Head Neck Surg 1998; 124: 513–8PubMedGoogle Scholar
  18. 18.
    Holmberg K, Juliusson S, Balder B, et al. Fluticasone propionate aqueous nasal spray in the treatment of nasal polyposis. Ann Allergy Asthma Immunol 1997; 78: 270–6PubMedCrossRefGoogle Scholar
  19. 19.
    Lildholdt T, Rundcrantz H, Lindquist N. Efficacy of topical corticosteroid powder for nasal polyposis: a double blind, placebo controlled study of budesonide. Clin Otolaryngol 1995; 20: 26–30PubMedCrossRefGoogle Scholar
  20. 20.
    Johansen L, Ilium P, Kristersen S, et al. The effect of budesonide (Rhinocort) in the treatment of small and medium sized polyps. Clin Otolaryngol 1993; 18: 524–7CrossRefGoogle Scholar
  21. 21.
    Rhuno J, Andersson B, Denburg J, et al. A double blind comparison of intranasal budesonide with placebo for nasal polyposis. J Allergy Clin Immunol 1990; 86: 946–53CrossRefGoogle Scholar
  22. 22.
    Holopainen E, Grahne B, Malmberg H, et al. Budesonide in the treatment of nasal polyposis. Eur J Respir Dis 1982; 63 Suppl. 122: 221–8Google Scholar
  23. 23.
    Lildholdt T, Rundcrantz H, Bende M, et al. Glucocorticoid treatment for nasal polyps. A study of budesonide powder and depot steroid injection. Allergy 1995; 50: 204–9Google Scholar
  24. 24.
    Tos M, Suendstrup G, Arndal H, et al. Efficacy of an aqueous and a powder formulation of nasal budesonide compared in patients with nasal polyps. Am J Rhinol 1998; 12/3: 183–9CrossRefGoogle Scholar
  25. 25.
    El-Naggar M, Kale S, Aldren C, et al. Effect of Beconase nasal spray on olfactory function in post-nasal polypectomy patients: a prospective controlled trial. J Laryngol Otol 1995; 109(10): 941–4PubMedGoogle Scholar
  26. 26.
    Dingsor G, Kramer J, Olsholt R, et al. Flunisolide nasal spray 0.025% in the prophylactic treatment of nasal polyposis after polypectomy. A randomized double blind parallel, placebo controlled study. Rhinology 1985; 23: 49–58Google Scholar
  27. 27.
    Drettner B, Ebbesen A, Nilsson M. Prophylactic treatment with flunisolide after polypectomy. Rhinology 1982; 20: 149–58PubMedGoogle Scholar
  28. 28.
    Hartwig S, Linden M, Laurent C, et al. Budesonide nasal spray as prophylactic treatment after polypectomy (a double-blind clinical trial). J Laryngol Otol 1988; 102: 148–51PubMedCrossRefGoogle Scholar
  29. 29.
    Karlsson G, Rundcrantz H. A randomized trial of intranasal beclomethasone dipropionate after polypectomy. Rhinology 1982; 20: 144–8PubMedGoogle Scholar
  30. 30.
    Virolainen E, Puhakka H. The effect of intranasal beclomethasone dipropionate on the recurrence of nasal polyps after ethmoidectomy. Rhinology 1980; 18: 9–18PubMedGoogle Scholar
  31. 31.
    Mygind N, Lund VJ. Intranasal steroids. Clinical Immunother 1996; 5: 122–36CrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Professorial Unit, Institute of Laryngology and OtologyRoyal National Throat, Nose and Ear HospitalLondonEngland

Personalised recommendations